Nuvation Bio Business Summary

Nuvation Bio Inc. (NUVB) is a commercial-stage biopharmaceutical company that generates revenue primarily through the commercialization of its lead oncology asset, IBTROZI (taletrectinib), a next-generation ROS1 inhibitor FDA-approved in June 2025 for ROS1-positive non-small cell lung cancer. The company’s revenue model is bifurcated between direct product sales in the U.S. and high-margin collaboration and licensing fees from strategic global partners, including Innovent Biologics in China, Nippon Kayaku in Japan, and a major 2026 global collaboration with Eisai. Nuvation’s business segments are focused on targeted small-molecule inhibitors and drug-drug conjugates (DDCs), with a late-stage pipeline led by safusidenib, which advanced to a pivotal Phase 3 trial for IDH1-mutant glioma in February 2026. Within the competitive landscape, Nuvation Bio competes directly with Nuvalent, Bristol Myers Squibb (repotrectinib), and Roche (entrectinib), positioning itself as a specialist in CNS-active therapies designed to overcome resistance and safety limitations of earlier-generation kinase inhibitors. Nuvation Bio was founded in 2018 by President and CEO David Hung, M.D., a renowned biopharma veteran who previously founded Medivation and led it to a $14.3 billion acquisition by Pfizer. The executive leadership team includes Chief Financial Officer Philippe Sauvage, formerly the CFO of Sanofi North America; Chief Medical Officer David Liu, M.D., Ph.D.; Chief Commercial Officer Colleen Sjogren, who previously led oncology launches at Medivation and Madrigal Pharmaceuticals; and Chief Technical Operations Officer David C. Hanley, Ph.D. The company is supported by a high-pedigree board of directors featuring Kathryn Falberg (former CFO of Jazz Pharmaceuticals), Robert Bazemore (former CEO of Epizyme), and newly appointed Robert Mashal, M.D. Notable institutional backing includes significant positions held by Omega Funds, Goldman Sachs, and Vanguard, reflecting strong investor confidence in the company’s transition from a clinical-stage developer to a global commercial oncology organization.